Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-105 alone and with Pembrolizumab in advanced solid tumors
NCT03809624Phase 1Terminated
- Sponsor
- Inhibrx Biosciences
- Start
- Jan 2019
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of inbrx-105 in solid tumor, non-small cell lung cancer (NSCLC), melanoma and 7 more (11 arms), sponsored by Inhibrx Biosciences. Primary endpoints: Frequency of adverse events of INBRX-105, Severity of adverse events of INBRX-105 and 1 more. Started Jan 2019; status: terminated.
02
Drugs
inbrx-105
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanomahead and neck squamous cell carcinoma (HNSCC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03809624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809624.